In this video commentary, Dr. David Brown reports on the 12-month outcomes of the BRAVO and CRUISE studies presented at ARVO 2010. What is the impact on retinal vein occlusion treatment?
In this video commentary, Dr. Katz comments on the interesting developments in drug therapy for glaucoma presented at ARVO 2010.
In this video commentary from ARVO 2010, Dr. Katz reports on exciting new modalities in the diagnosis of glaucoma. How will they affect clinical practice?
In this video blog, David M. Brown, MD, provides a commentary about retinal vein occlusion treatment, focusing on recent clinical trial data as well as newly approved drug devices.
Is anti-VEGF therapy more effective than the standard of care for retinal vein occlusions? In this video blog, David M. Brown, MD, reflects on the recent BRAVO and CRUISE clinical trial results.
Will the results of the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study affect retinal vein occlusion treatment? David M. Brown, MD, summarizes the data in this video blog.
Because optic nerve damage is a sign of glaucoma, baseline documentation of the optic nerve in all patients for later comparison is important. David M. Brown, MD, explains in this video blog.
The high cost of prescription medications can often prevent patient compliance. In this video blog, David M. Brown, MD, offers advice for prescribing drugs to cost-conscious patients.
In this video commentary, Dr. David Brown shares tips for using SD-OCT imaging in the perioperative period of cataract surgery to boost surgical success and patient satisfaction.
Dr. Jeffrey Lieberman discusses the ethics of disclosing or selling clinician prescribing data to private entities such as drug manufacturers.